HMCN1 as a conserved biomarker of epithelial–mesenchymal transition: a cross-cancer analysis
This study identifies <i>HMCN1</i> as a novel, conserved regulator of EMT and a candidate prognostic biomarker across cancers. The findings in osteosarcoma provide a foundational rationale for developing <i>HMCN1</i> as a potential therapeutic target.
Authors
- Yayun Liu (ORCID: https://orcid.org/0000-0002-2806-7640)
- Zhi Liu (ORCID: https://orcid.org/0000-0001-9340-962X)
- Yuanxi Leng
Institutions
- Jiangxi University of Traditional Chinese Medicine (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.3389/fonc.2025.1730887
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00